Combination of Nivolumab and Ipilimumab in Advanced Melanoma Shows Tumor Shrinkage

Sun, 2013-06-02

 
BREAKING NEWS: A number of important melanoma research updates have emerged from the 2013 American Society of Clinical Oncology (ASCO) annual meeting, including a report on Sunday, June 2 about the combination of ipilimumab and nivolumab. Both drugs are designed to engage the immune system in fighting melanoma. In the study, the combined drugs helped shrink tumors in 38% of patients overall. One arm of the study generated a 52% response rate in patients. The study has been published online in the New England Journal of Medicine.